V. Ramasamy

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies

S. Jain, S. Swaminathan, R. Shukla, 2016, BMC Biotechnology.

Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models

F. Krammer, Julia A. Brown, A. Lal, 2020, EBioMedicine.

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice

R. Johnston, R. Ahmed, A. D. de Silva, 2018, PLoS neglected tropical diseases.

Application of Deep Learning Strategies to Assess COVID-19 Patients

C. Panigrahi, S. Peng, J. Sarkar, 2021 .

Next generation designer virus-like particle vaccines for dengue

H. Beesetti, S. Swaminathan, R. Shukla, 2019, Expert review of vaccines.

Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine

R. Shukla, R. Ahuja, Rajgokul K. Shanmugam, 2020, Frontiers in Cellular and Infection Microbiology.

Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement

F. Krammer, S. Swaminathan, Jean K. Lim, 2020, EBioMedicine.

Fuzzy and Position Particle Swarm Optimized Routing in VANET

Praveena Ramalingam, V. Ramasamy, Jagatheswari Srirangan, 2021, International journal of electrical and computer engineering systems.

Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice

R. Shukla, N. Khanna, Charu Aggarwal, 2023, Frontiers in Immunology.

Pichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation.

S. Swaminathan, R. Shukla, Rajgokul K. Shanmugam, 2019, Pathogens and disease.